x

Join Advarra

Learn more about our company team, careers, and values. Join Advarra’s Talented team to take on engaging work in a dynamic environment.

See Jobs

Daniel Eisenman, PhD, RBP, SM(NRCM), CBSP

Executive Director, Biosafety Services, Advarra

Prior to joining Advarra, Daniel Eisenman served as Biosafety Officer at UNC Chapel Hill and the Medical University of South Carolina. Eisenman holds a PhD in Molecular Biology and Immunology from Augusta University, as well as various professional certifications in biological safety, including the Registered Biological Safety Professional (RBP) and Certified Biological Safety Professional (CBSP) certifications through the American Biological Safety Association (ABSA) and as a Specialist Microbiologist in Biological Safety (SM(NRCM)) through the American Society for Microbiology (ASM) National Registry of Certified Microbiologists (NRCM). He is also a devoted longtime educator, having taught microbiology at the undergraduate and graduate levels. Eisenman currently serves on the ABSA Owned Course Committee and is a regular speaker at clinical research conferences.

Dan Eisenman

Latest Posts by Daniel

 
Webinar

Biosafety, Ethical, and Logistical Challenges to Pursuing a Coronavirus Vaccine at Warp Speed

The SARS-CoV-2 pandemic has impacted all aspects of society. Various government and private groups around the world are endeavoring to develop safe and effective vaccines at an unprecedented pace and scale to quell the pandemic as quickly as possible.

Watch Now
Read more
 
Blog

mRNA and Its Role in Clinical Research

Messenger RNA (mRNA) has made recent headlines due to its role in Operation Warp Speed. This article explores how its technology is used to fight the COVID-19 pandemic.

Read Now
5 min. read
Read more
 
Blog

Does Warp Speed Vaccine Development and Testing Compromise Safety?

Fiction often shows warp speed travels not going as planned, but what does warp speed mean for vaccine development in clinical research?

Read Now
4 min. read
Read more
 
Blog

Q&A – Study Startup Success for the New Generation of Genetically Engineered Vaccines

Daniel Eisenman answers questions from his latest webinar Study Startup Success for the New Generation of Genetically Engineered Vaccines.

Read Now
2 min. read
Read more
 
Blog

Q&A Part 1 – Gene Therapy Research in the Age of COVID-19

Panelists from Advarra’s inaugural virtual symposium participated in a Q&A session to address questions submitted by the audience. Read part 1:

Read Now
5 min. read
Read more
 
Blog

Q&A Part 2 – Gene Therapy Research in the Age of COVID-19

Expert panelists from Advarra’s gene therapy virtual symposium address some of the most popular questions submitted by the audience. Read part 2:

Read Now
4 min. read
Read more
 
Blog

Safety Precautions for Laboratory Research With COVID-19 Specimens

The pandemic has brought biosafety to the spotlight. This blog discusses guidelines and safety precautions for handling COVID-19 specimens.

Read Now
7 min. read
Read more
 
Webinar

Preparing for Multisite Gene Therapy Studies

August 27, 2019

The fast and dramatic growth in the field of gene therapy is unprecedented, as the US FDA and regulatory agencies of several other countries have begun issuing approvals for licensed ...

Watch Now
Read more
 
Blog

Infection Control and Biosafety in Gene Therapy Research

Given the growth in gene therapy research, sponsors, CROs and sites have become increasingly curious about the requirements to be able to conduct such studies.

Read Now
4 min. read
Read more
 
Webinar

An Introduction to Human Gene Transfer Research and Institutional Biosafety Committees (IBCs)

Daniel Eisenman discusses the basics of research involving genetic engineering and the role played by the IBC in ensuring research is conducted safely and responsibly.

Watch Now
Read more
 
Blog

Planning Gene Therapy Research? Plan for IBC Review

The completion of the human genome project and advances in genetic engineering have paved the way for clinical trials involving human gene transfer

Read Now
4 min. read
Read more